DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

 

Molecular Imaging Homepage

Phase I trial demonstrates safe use of radiotracer produced in minutes Manufactured using a Ga-68 generator and a cold kit vial

Bracco Imaging acquires SurgVision Enables development of a real-time fluorescence image-guided surgery platform

Blue Earth Diagnostics inks Axumin deal with Seibersdorf Laboratories Manufacturing and distribution in certain European countries

Two new imaging agents may help physicians make better and quicker treatment decisions Could determine therapy response in 24 hours

Researchers develop targeted alpha therapy protocol for prostate cancer Determines most effective therapy with the least number of side effects

Eyeing theranostics, Sofie Biosciences completes acquisition of Zevacor Pharma Growth of FDG also influenced decision

Blue Earth Diagnostics partners with GE to manufacture Axumin PET agent in UK Agreements were made in other European countries

RefleXion Medical selects MedCrypt to secure its new radiotherapy technology Updated FDA guidelines put cybersecurity at forefront

PET imaging used for the first time to evaluate Zika virus in mouse model May aid in development of therapeutic agents

Philips introduces its CardioMD IV SPECT system at ASNC meeting Smaller footprint and lower cost of ownership

Courtesy of Dr. Kambiz Rahbar

New therapeutic agent shows promise for treating deadly type of prostate cancer

by Lauren Dubinsky , Senior Reporter
A new therapeutic agent for radioligand therapy called lutetium-177-labeled PSMA-617 is showing promise in a German multi-center study for treating patients with metastatic castration-resistant prostate cancer. The research was recently published in The Journal of Nuclear Medicine.

Lu-177-PSMA-617 shows efficacy in patients independent of prior therapies,” Dr. Kambiz Rahbar of the University Hospital Muenster, told HCB News. “It has a favorable toxicity profile, especially compared to cytotoxic chemotherapy.”

Story Continues Below Advertisement

CT, MRI, NM, SPECT/CT, PET & PET/CT service, refurbished systems and parts

Accelerate your ROI with our Black Diamond Certified refurbished systems. One year warranty - ISO 13485 Certified - FDA registered - Over 65k parts in inventory DOTmed Certified



Prostate-specific membrane antigen is overexpressed in prostate cancer, especially with castration-resistant disease. mCRPC is usually responsible for prostate cancer deaths and the median survival for men with the disease is less than two years.

As part of the study, 145 patients with mCRPC were treated with Lu-177-PSMA-617 at 12 therapy centers across Germany from February 2014 to July 2015. Each patient received one to four therapy cycles and a total of 248 therapy cycles were performed.

45 percent of patients had a positive
response following all therapy cycles
If the prostate-specific antigen amount decreased by 50 percent or more at least two weeks after the start of the therapy, the researchers considered it effective. They found that 45 percent of patients had a positive response after all of the therapy cycles and 40 percent responded after one cycle.

The patients experienced a few manageable side effects including hematoxicity, anemia, thrombocytopenia, leukopenia and dry mouth.

The researchers concluded that Lu-177-PSMA-617 radioligand therapy is safe and more effective than other third-line systemic therapies for mCRPC patients. However, more studies are needed to further validate its effectiveness in order for it to receive FDA approval.

“We think Lu-177-PSMA-617 will provide an additional therapeutic option for mCRPC and maybe as an additive therapy to established therapies at earlier stages to improve outcome,” said Rahbar.

Molecular Imaging Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2017 DOTmed.com, Inc.
ALL RIGHTS RESERVED